3P Biopharmaceuticals and Buzzard Pharmaceuticals start a cGMP manufacturing collaboration to develop a new treatment to combat solid tumours

3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for cGMP manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organisation CDMO specialized in the process development and GMP manufacturing of biologics and Buzzard Pharmaceuticals, a Swedish pharmaceutical company developing and re-positioning drugs in oncology.

Buzzard and 3P began their collaboration at the end of last year when 3P was selected as the cGMP manufacturing partner for Buzzard’s oncology drug Isunakinra. This molecule was previously developed for eye indications but based on a strong scientific rationale for IL-1 inhibition in cancer treatment Buzzard is re-positioning the drug for cancer indications. A phase I/II clinical trial in solid tumor patients was initiated at the Baylor Research Institute in Dallas (Texas) in 2020.

3P Bio cGMP manufacturing partners with Buzzard Pharmaceuticals.

Cytokines are small proteins that are crucial in controlling the growth and activity of immune cells and blood cells. There are different kinds of cytokines, and interleukin-1 (IL-1) is one of the most important. Chronic inflammation mediated by IL-1 signaling leads to tumor immune suppression, triggers suppression of adaptive immunity, tumour promotion, and metastasis. Isunakinra is a recombinant protein that potently inhibits signaling of both IL-1 alpha and IL-1 beta through the IL-1 receptor. Based on these functions for IL-1 in the tumor micro-environment, Isunakinra is being studied in cancer indications.

Dámaso Molero, CEO at 3P Biopharmaceuticals added: “We are pleased to be a part of this project aimed at combatting the cancer, this multifactorial global disease. We are going to collaborate to provide more opportunities to cancer suffering patients.”

Maarten de Château, CEO at Buzzard Pharmaceuticals added: “We are very pleased to work with 3P Bio on our exciting recombinant protein project, including production of GMP material for our planned expansion study in solid tumor patients. We find that 3P Bio has a very professional approach and flexible way of working with our project.”

Our dedicated team of specialists will be happy to discuss any of your cGMP manufacturing needs. Contact us on +34 948 346 480 or email itswithinus@3pbio.com

Related Content

Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19
Read more

Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE

Elena Erroba, Director of Business Development, Communication and Marketing at 3P Biopharmaceuticals, has been elected as Navarra’s Businesswoman of the Year 2021
Read more

3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA

The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.